References.
- Pearson ADJ, Rossig C, Lesa G, et al . ACCELERATE and European
medicines agency paediatric strategy forum for medicinal product
development of checkpoint inhibitors for using combination therapy in
paediatric patients. Eur J Cancer 2020; 127 : 52-66.
- Siegel RL, Miller KD, Jemel A. Cancer statics. CA Cancer J Clin 2016;
66 : 7-30.
- PDQ® Pediatric Treatment Editorial Board. PDQ cancer
Information Summaries [Internet] . Late effect pf treatment.
Bethesada (MD), National Cancer Institute 2002-2020.2020,Feb 4.
- Leung W, Naele G, Behm F, et al. Deficient innate immunity,
thymopoiesis, and gene expression response to radiation in survivors
of childhood acute lymphoblastic leukemia. Cancer Epidemiology 2010;
34: 303-308
- Takahashi R, Ishibashi Y, Hiraoka K, et al . Phase Ⅱ study of
personalized peptide vaccination for refractory bone and soft tissue
sarcoma patients. Cancer Sci 2013; 104:1285-1294.
- Iwasa S, Yamada Y, Heike Y, et al. PhaseⅠstudy of a new cancer
vaccine of ten mixed peptides for advancer cancer patients. Cancer Sci
2016; 107: 590-600.
- Takahashi R, Toh U, Iwakuma N, et al . Feasibility study of
personalized peptide vaccination for metastatic recurrent
triple-negative breast cancer patients. Breast Cancer Resarch 2014;
16: R70.
- Noguchi M, Moriya F, Koga N et al . A randomized phase Ⅱ
clinical trial of personalized peptide vaccination with metronomic
low-dose cyclophosphamide in patients with metastatic
castration-resistant prostate cancer. Cancer Immunol Immunother 2016;
65 :151-60.
- Suekane S, Ueda K, Nishihara K, et al . Personalized peptide
vaccination as a second line treatment for metastatic upper tract
urothelial carcinoma. Cancer Sci 2017; 108 :2430-2437.
- Sakamoto S, Yutani S, Schichijo S, et al . Immunological
evaluation of personalized peptide vaccination for patients with
histologically unfavorable carcinoma of unknown primary site. Cancer
Immuno Immunother 2016; 65: 1223-1231.
- Sakamoto S, Matsueda S, Takamori S, et al . Immunological
evaluation of personalized peptide vaccination for cancer patients
with the HLA-A26 allele. Cancer Sci 2015; 106: 1257-1263.
- Komatsu N, Shichijo S, Nakagawa M, et al . New multiplexed flow
cytometric assay to measure anti-peptide antibody: a novel tool for
monitoring immune responses to peptides used for immunization. Scand J
Clin Laborat Invest 2004; 64: 535-546.
- Chen C, Garcia HK, Sheer M. Current and future treatment strategies
for Rhabdomyosarcoma. Front Oncol 2019; 9:1958.
- Camero S, Ceccarelli S, De Feris M, et al . PARP inhibitors
affects survival, radiation susceptibility of human alveolar and
embryonal rhabdomyosarcoma cell lines. J Cancer Res Clin Oncol 2019;
145:137-152.
- Stewart E, Mcvoy J, Wang H, et al . Identification of
therapeutic targets-rhabdomyosarcoma integrated genomic, epigenomic,
and proteomic analysis. Cancer cell 2018; 34 : 411-426.
- Hawkins DS, Chi YY, Anderson R, et al. Additional vincristine
and irinotecan to vincristine, dactinomycin, and cyclophosphamide does
not improve outcome for intermediate-risk rhabdomyosarcoma : a report
from the Children’s Oncology Group. J Clin Oncol 2018; 36 : 2770-2777.
- Kim JR, Yoon HM, Koh KM, et al. Rhabdomyosarcoma in children
and adolescents : patterns and risk factors of distant metastasis. Am
J Roentgenol 2017; 209 :409-416.
- Amer KM, Thomson JE, Conquesta G, et al . Epidemiology,
incidence and survival of rhabdomyosarcoma subtypes : SEER and ICES
data base analysis. J Orthop Res 2019; 37: 2226-2230.
- Hashii Y, Sato E, Ohta H, et al. WT1 Peptide immunotherapy for cancer
in children and young adults. Pediatr Blood Cancer 2010; 55:352-355.